Terry Hermiston

Title: Innovations of Terry Hermiston: A Pioneer in Extracellular Vesicles and Factor VII Peptides

Introduction

Terry Hermiston, based in Corte Madera, California, is a notable inventor recognized for his significant contributions to the field of biopharmaceuticals, notably through his 30 patents. His innovative approaches have paved the way for advancements in targeted therapies, which play a crucial role in the treatment of acute bleeding and similar disorders.

Latest Patents

Among his recent patents, one highlights a novel **Method of targeting exosomes**. This patent describes a technique for targeting extracellular vesicles using a molecule that comprises a GLA domain. The method focuses on improving therapeutic delivery mechanisms using these vesicles. Another important patent, **Short-acting Factor VII polypeptides**, introduces peptides that have a shortened half-life, which is ideal for treating acute bleeding conditions. This innovation involves modifying the sialylation and/or glycosylation of Factor VII, creating variants that are useful in managing critical bleeding situations.

Career Highlights

Terry has had a remarkable career, working with reputable companies such as Onyx Pharmaceuticals and Psioxus Therapeutics. His contributions have had a lasting impact in the biopharmaceutical sector, as he has consistently worked at the forefront of innovation in drug development and therapeutic solutions.

Collaborations

Throughout his career, Terry has collaborated with esteemed professionals like Maxine Bauzon and Irene Kuhn. These collaborations have not only aided in the development of groundbreaking technologies but have also fostered a spirit of teamwork and innovation in the research community.

Conclusion

Terry Hermiston's extensive patent portfolio and his commitment to advancements in the biopharmaceutical industry underscore his status as a pioneering inventor. His work continues to inspire new innovations that address critical healthcare needs, particularly in the realm of targeted therapies for acute medical conditions.